Novo Nordisk launches NovoSeven® with pre-filled syringe for fast bleeding control

Novo Nordisk announced today that NovoSeven® is now available with a pre-filled syringe that will support rapid treatment of bleeding episodes in haemophilia patients with inhibitors.

NovoSeven® with pre-filled syringe is a system designed to meet patients’ needs in terms of speed of reconstitution, ease of use, reliability and portability. The pre-filled syringe speeds up the reconstitution process since it is no longer necessary to draw the solvent into the syringe separately.

“Novo Nordisk constantly strives to make advancements for patients. With this latest development we show our commitment to improve the lives of people with haemophilia in every way possible,” said Paul Huggins, corporate vice president, Biopharm Global Marketing & Medical Affairs.

NovoSeven® with the new pre-filled syringe builds on Novo Nordisk’s strong heritage with NovoSeven® in a 3-year room temperature stable formulation and represents another milestone in the company’s commitment to changing possibilities in haemophilia.

In the EU, the product will be called ‘NovoSeven® with pre-filled syringe’, and in the US it will be named ‘NovoSeven® RT with MixPro™’. The new device has been approved by both the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) in October 2012.

References

1. Lusher JM. Eur J Haematol 1998; 61(63): 7–10.